

# Antonio Cigliano, PhD

Assistant Professor

**CONTACT INFO**  
antonio.cigliano@unicamillus.org  
Unicamillus-International University of Health  
and Medical Sciences, Roma

## EDUCATION

**2021** Achieved the National Scientific Qualification (ASN) as associate in the Italian higher education system, in the call 2018/2020 (Ministerial Decree n. 2175/2018) for the disciplinary field of 06/A2 - Experimental medicine, pathophysiology and clinical pathology. (Academic Recruitment Field 06/A - Pathology and laboratory medicine, according to the national classification). Validity 11 years from 05/31/2021 to 05/31/2032.

**2005-2009** PhD in Biochemistry, Biology and Molecular Biotechnologies obtained at the University of Sassari. Thesis: "Aortic and pulmonary bioprosthetic heart valves: an insight on glycosaminoglycan distribution and fine structure in decellularized porcine scaffolds for tissue engineering purposes." Supervisor: **Professor Marilena Formato**.

**2005** Master's degree in Biological Sciences at University of Sassari. Thesis: "Content and distribution of glycosaminoglycans in valve tissue and pericardium from animal species by xeno-transplant." Supervisor: **Professor Marilena Formato**.

## WORK EXPERIENCE

**01/10/2025** Associate Professor **GSD 06/MEDS-02 Pathology and laboratory medicine, SSD MEDS-02/B Laboratory medicine** at the Unicamillus-International University of Health and Medical Sciences, Roma

**01/03/2025** Associate Professor **GSD 06/MEDS-02 Pathology and laboratory medicine, SSD MEDS-02/A Pathology** at the University of Sassari

**2022 – 2025** **Type B fixed-term researchers (RTDB) (Assistant professor)** in the Field 06/A2 (MED/04) - Pathology and laboratory medicine, according to the national classification in the Department of Medicine, Surgery and Pharmacy, University of Sassari.

**2018-2020** **Senior Researcher and lab manager** under the supervision of **Professor Diego F. Calvisi** at the Institute of Pathology University Hospital Regensburg (DE).

**2017-2018** **Senior Researcher** in the Laboratory of Personalized Medicine under the supervision of **Scientific Director Gianluigi Giannelli** at the National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, Italy.

**2011- 2017** **Post Doc** position in **Professor Diego F. Calvisi's lab** in the Institute of Pathology at the University Medicine of Greifswald (DE). Starting Project: Inhibition of fatty acid synthase, PI3Kinase/AKT/mTOR, and MAPKinase in mouse and rat models of liver carcinogenesis.

- 2011** Between August and September 2011 held a position in **Professor Xin Chen's lab** in the Department of Biopharmaceutical Sciences in the School of Pharmacy at the University of California, San Francisco. General responsibilities were assisting in DNA microarrays to explore pattern of gene expression in mouse cell models for liver cancer and gastric cancer and learning the hydrodynamic gene delivery method in mice.
- 2010-2011** **Post Doc** position under the supervision of **Professor Marilena Formato** at the University of Sassari - Department of Physiologic, Biochemical and Cellular Sciences.
- 2008-2009** **Visiting Scientist** in **Professor Alfonso Bellacosa's lab** at Fox Chase Cancer Center, Philadelphia (PA) United States.

## FUNDED PROJECTS

- 2023** PRIN 2022 - Disruption of the tumor microenvironment as an innovative therapeutic strategy against intrahepatic cholangiocarcinoma – PI Prof. Diego F. Calvisi
- 2023** AIRC (Italian Association for Cancer Research) - Targeting the translation initiation machinery as a novel therapy against human hepatocellular carcinoma – PI Prof. Diego F. Calvisi
- 2017 – 2018** AIRC (Italian Association for Cancer Research) - Targeting Notch Pathway for personalizing therapy in Cholangiocarcinoma – PI Prof Gianluigi Giannelli
- 2015 – 2018** DFG n. 286541313 (Deutsche Forschungsgemeinschaft) - Der PI3K/AKT/mTOR-Signalweg in glykogenspeichernden hepatozellulären Läsionen des Menschen und im murinen kombinierten ChREBP-Knockout- und Inseltransplantationsmodell – PI Dr. Silvia Ribback
- 2011 - 2014** DFG n. 201664920 (Deutsche Forschungsgemeinschaft) - Inhibition of fatty acid synthase, PI3Kinase/AKT/mTOR, and MAPKinase in rats with hepatocarcinogenesis – PI Prof. Dr. Matthias Evert

## TEACHINGS AND COURSES

- 2013** Student supervision PhD candidate Giulia Pilo, from University of Sassari, during her time abroad (12 months) at the Institute of Pathology University of Greifswald.
- 2015** Student supervision PhD candidate Marta Mela, from University of Sassari, during her time abroad (5 months) at the Institute of Pathology University of Greifswald.
- 2016** Student supervision PhD candidate Marta Szydłowska, from University of Cagliari, during her time abroad (6 months) at the Institute of Pathology University of Greifswald.
- 2016** Student supervision Bachelor Student Marina Serra, from University of Sassari, during her time abroad (1 month) at the Institute of Pathology University of Greifswald.
- 2018** Student supervision Bachelor Student Chiara Mura, from University of Cagliari, during her time abroad (3 months) at the Institute of Pathology University of Regensburg.
- 2019** Student supervision Master Student Mauro Passaretti, from University of Cagliari, during his time abroad (3 months) at the Institute of Pathology University of Regensburg.
- 2019** Student supervision PhD candidate Graziella Peitta, from University of Sassari, during her

time abroad (6 months) at the Institute of Pathology University of Regensburg.

- 2019** Supervision of visiting scientist Vildan Torun from University of Ankara, during her time abroad (3 months) at the Institute of Pathology University of Regensburg.
- 2022/23** Lecturer of General Pathology (12hours of teaching, 1 ECTS) which is a module embedded in the teaching “Biomedical Science” for the Bachelor students in “IMAGING AND RADIOTHERAPY TECHNIQUES (L/SNT3)”, Department of Medicine, Surgery and Pharmacy, University of Sassari.
- 2022/23** Lecturer of Biochemistry (24hours of teaching, 2 ECTS) which is a module embedded in the teaching “Biology, Biochemistry and general Microbiology” for the Bachelor students in “NURSING (L/SNT1)”, Department of Medicine, Surgery and Pharmacy, University of Sassari.
- 2022/23** Seminar on “**Animal models for human liver cancer: Hydrodynamic gene delivery technique**” in the teaching “General Pathology” for the Master students in Pharmacy, University of Sassari.
- 2023/24** Lecturer of General Pathology (12 hours of teaching, 1 ECTS) which is a module embedded in the teaching “Biomedical Science” for the Bachelor students in “IMAGING AND RADIOTHERAPY TECHNIQUES (L/SNT3)”, Department of Medicine, Surgery and Pharmacy, University of Sassari.
- 2023/24** Lecturer of Cell Culture Laboratory techniques (10 hours of teaching, 1 ECTS) which is a module embedded in the teaching “Physiology and Genetic” for the Bachelor students in “Biomedical Laboratory Techniques (L/SNT3)”, Department of Medicine, Surgery and Pharmacy, University of Sassari.
- 2024/25** Lecturer of General Pathology (12 hours of teaching, 1 ECTS) which is a module embedded in the teaching “Biomedical Science” for the Bachelor students in “IMAGING AND RADIOTHERAPY TECHNIQUES (L/SNT3)”, Department of Medicine, Surgery and Pharmacy, University of Sassari.
- 2024/25** Lecturer of Cell Culture Laboratory techniques (10 hours of teaching, 1 ECTS) which is a module embedded in the teaching “Physiology and Genetic” for the Bachelor students in “Biomedical Laboratory Techniques (L/SNT3)”, Department of Medicine, Surgery and Pharmacy, University of Sassari.
- 2024/25** Lecturer of General Pathology (40 hours of teaching, 5 ECTS) master course in “Biotechnology for Human and Animal Health” (LM-9), Department of Veterinary medicine, University of Sassari.

## **ACTIVITIES AS PART OF THE PHD SCHOOL PROGRAMME - UNIVERSITY OF SASSARI**

- 2022 to present** **Member of the doctorate school committee** of the PhD course in “LIFE SCIENCES AND BIOTECHNOLOGIES” (UNISS) **38<sup>th</sup>, 39<sup>th</sup>, 40<sup>th</sup>, 41<sup>st</sup> Cycle**
- 2023** **Supervisor** PhD candidate Qian Wang as part of PhD school in “LIFE SCIENCES AND BIOTECHNOLOGIES” – **38<sup>th</sup> Cycle**

## SCIENCE DISSEMINATION ACTIVITIES

<b>11/05/2025</b>	Foundraising event “L’azalea della Ricerca 2025” 11 <sup>th</sup> of May 2025 together with the AIRC (Italian Association Cancer Research) volunteers
<b>25/01/2025</b>	Foundraising event “Le arance della salute 2025” 25 <sup>th</sup> of January 2025 together with the AIRC (Italian Association Cancer Research) volunteers
<b>09/11/2024</b>	Foundraising event “I cioccolatini della Ricerca 2024” 9 <sup>th</sup> November 2024 together with the AIRC (Italian Association Cancer Research) volunteers
<b>17/10/2024</b>	Foundraising event for AIRC (Italian Association Cancer Research). During the event I spoke about our research and how the funds granted from AIRC are managed in our laboratory. 17 <sup>th</sup> of October 2024, Borgo degli Ulivi Sorso, Sassari.
<b>27/09/2024</b>	Partecipation to “Notte Europea dei Ricercatori” – SHARPER (SHARing Researches' Passion for Enhanced Roadmaps) as AIRC researcher, 27 <sup>th</sup> September 2024
<b>12/05/2024</b>	Foundraising event “L’azalea della Ricerca 2025” 12 <sup>th</sup> of May 2024 together with the AIRC (Italian Association Cancer Research) volunteers
<b>27/01/2024</b>	Foundraising event “Le arance della salute 2025” 27 <sup>th</sup> of January 2025 together with the AIRC (Italian Association Cancer Research) volunteers
<b>08/11/2023</b>	Meeting with the students of “ Liceo Classico D.A. Azuni in Via Rolando 4 Sassari”, 8 <sup>th</sup> November 2023 as AIRC researcher to talk about scientific projects
<b>29/09/2023</b>	Partecipation to “Notte Europea dei Ricercatori” – SHARPER (SHARing Researches' Passion for Enhanced Roadmaps) as AIRC researcher, 29 <sup>th</sup> September 2023

## METRICS & PUBLICATIONS 01/10/2025

77 publications in peer reviewed journal (Pubmed: 76; Scopus: 77)

Scopus Author ID: **35067863300**

*h*-Index 31  
Citazioni totali 3634

ResearcherID: **J-4660-2017**

*h*-Index 30  
Citazioni totali 3449

Google Scholar

*h*-Index 37  
Citazioni totali 5051

ID ORCID: **0000-0002-6408-3613**

1. Gäbele E, Gigante I, Pastore M, **Cigliano A**, Galleri G, Bauer T, Pizzuto E, Mancarella S, Müller M, Marra F, Siegmund H, Giannelli G, Evert M, Raggi C, Calvisi DF, Steinmann SM. The DNA Minor

- Groove Binders Trabectedin and Lurbinectedin Are Potent Antitumor Agents in Human Intrahepatic Cholangiocarcinoma. *Int J Mol Sci* 2025 Sep 18 doi: 10.3390/ijms26189085
2. Mi W, **Cigliano A**, Galleri G, Gigante I, Steinmann SM, Cibali E, Serra M, Pes GM, Schloesser D, Pizzuto E, Siegmund H, Fischer C, Saborowski A, Giannelli G, Evert M, van der Laan LJW, Versteegen MMA, Calvisi DF. Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinoma. *JHep Reports*. 2025 Apr 3 doi: 10.1016/j.jhepr.2025.101416
  3. **Cigliano A**, Gigante I, Serra M, Vidili G, Simile MM, Steinmann S, Urigo F, Cossu E, Pes GM, Dore MP, Ribback S, Milia EP, Pizzuto E, Mancarella S, Che L, Pascale RM, Giannelli G, Evert M, Chen X, Calvisi DF. HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma. *J Exp Clin Cancer Res*. 2024 Sep 6;43(1):253. doi: 10.1186/s13046-024-03177-7
  4. **Cigliano A**, Liao W, Deiana GA, Rizzo D, Chen X and Calvisi DF. Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges. *Biomedicines* 2024, 12, 1624. doi:10.3390/biomedicines12071624
  5. **Cigliano A**, Simile MM, Vidili G, Pes GM, Dore MP, Urigo F, Cossu E, Che L, Feo C, Steinmann SM, Ribback S, Pascale RM, Evert M, Chen X and Calvisi DF. Fatty Acid Synthase Promotes Hepatocellular Carcinoma Growth via S-Phase Kinase-Associated Protein 2/p27KIP1 Regulation. *Medicina* 2024, 60, 1160. doi:10.3390/medicina60071160.
  6. **Cigliano A**, Alastair J. Strain and Cadamuro M. Signalling and molecular networks related to development and inflammation involved in CCA initiation and progression. *Hepatoma Research*. 2023 doi: 10.20517/2394-5079.2023.09.
  7. **Cigliano A**, Zhang S, Ribback S, Steinmann S, Sini M, Ament CE, Utpatel K, Song X, Wang J, Pilo MG, Berger F, Wang H, Tao J, Li X, Pes GM, Mancarella S, Giannelli G, Dombrowski F, Evert M, Calvisi DF, Chen X, Evert K. Correction: The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease. *J Exp Clin Cancer Res*. 2023 May 17;42(1):124. doi: 10.1186/s13046-023-02709-x. Erratum for: *J Exp Clin Cancer Res*. 2022 Jun 3;41(1):192
  8. Mancarella S, Serino G, Gigante I, **Cigliano A**, Ribback S, Sanese P, Grossi V, Simone C, Armentano R, Evert M, Calvisi DF, Giannelli G. Correction: CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype. *J Exp Clin Cancer Res*. 2023 Apr 18;42(1):88. doi: 10.1186/s13046-023-02661-w. Erratum for: *J Exp Clin Cancer Res*. 2022 Feb 16;41(1):65.
  9. Steinmann SM, Sánchez-Martín A, Tanzer E, **Cigliano A**, Pes GM, Simile MM, Desaubry L, Marin JJG, Evert M, Calvisi DF. eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. *Int J Mol Sci*. 2023 Jan 20;24(3):2055. doi: 10.3390/ijms24032055.
  10. **Cigliano A**, Zhang S, Ribback S, Steinmann S, Sini M, Ament CE, Utpatel K, Song X, Wang J, Pilo MG, Berger F, Wang H, Tao J, Li X, Pes GM, Mancarella S, Giannelli G, Dombrowski F, Evert M, Calvisi DF, Chen X, Evert K. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease. *J Exp Clin Cancer Res*. 2022 Jun 3;41(1):192. doi: 10.1186/s13046-022-02394-2.
  11. Che L, Paliogiannis P, **Cigliano A**, Pilo MG, Chen X, Calvisi DF. Corrigendum: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma. *Front Oncol*. 2022 Apr 12;12:874053. doi: 10.3389/fonc.2022.874053. Erratum for: *Front Oncol*. 2019 Dec 11;9:1412.
  12. Mancarella S, Serino G, Gigante I, **Cigliano A**, Ribback S, Sanese P, Grossi V, Simone C, Armentano R, Evert M, Calvisi DF, Giannelli G. CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype. *J Exp Clin Cancer Res*. 2022 Feb 16;41(1):65. doi: 10.1186/s13046-022-02283-8.
  13. Wang H, Zhang S, Zhang Y, Jia J, Wang J, Liu X, Zhang J, Song X, Ribback S, **Cigliano A**, Evert M, Liang B, Wu H, Calvisi DF, Zeng Y, Chen X. Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [*J Hepatol* (2022) 123-134]. *J Hepatol*. 2022 Mar;76(3):755-756. doi: 10.1016/j.jhep.2021.12.006. Erratum for: *J Hepatol*. 2022 Jan;76(1):123-134.

14. Scheiter A, Evert K, Reibenspies L, **Cigliano A**, Annweiler K, Müller K, Pöhmerer LM, Xu H, Cui G, Itzel T, Materna-Reichert S, Coluccio A, Honarnejad K, Teufel A, Brochhausen C, Dombrowski F, Chen X, Evert M, Calvisi DF, Utpatel K. RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues. *Mol Oncol*. 2022 Mar;16(5):1091-1118. doi: 10.1002/1878-0261.13135.
15. Simile MM, **Cigliano A**, Paliogiannis P, Daino L, Manetti R, Feo CF, Calvisi DF, Feo F, Pascale RM. Nuclear localization dictates hepatocarcinogenesis suppression by glycine N-methyltransferase. *Transl Oncol*. 2022 Jan;15(1):101239. doi: 10.1016/j.tranon.2021.101239. Epub 2021 Oct 12.
16. Wang H, Zhang S, Zhang Y, Jia J, Wang J, Liu X, Zhang J, Song X, Ribback S, **Cigliano A**, Evert M, Liang B, Wu H, Calvisi DF, Zeng Y, Chen X. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis. *J Hepatol*. 2022 Jan;76(1):123-134. doi: 10.1016/j.jhep.2021.08.021.
17. **Cigliano A**, Chen X, Calvisi DF. Current challenges to underpinning the genetic basis for cholangiocarcinoma. *Expert Rev Gastroenterol Hepatol*. 2021 May;15(5):511-526. doi: 10.1080/17474124.2021.1915128.
18. Wang H, Song X, Liao H, Wang P, Zhang Y, Che L, Zhang J, Zhou Y, **Cigliano A**, Ament C, Superville D, Ribback S, Reeves M, Pes GM, Liang B, Wu H, Evert M, Calvisi DF, Zeng Y, Chen X. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans. *Hepatology*. 2021 Jul;74(1):248-263. doi: 10.1002/hep.31692.
19. Wang H, Wang J, Zhang S, Jia J, Liu X, Zhang J, Wang P, Song X, Che L, Liu K, Ribback S, **Cigliano A**, Evert M, Wu H, Calvisi DF, Zeng Y, Chen X. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis. *Cell Mol Gastroenterol Hepatol*. 2021;11(4):1095-1117. doi: 10.1016/j.jcmgh.2020.11.008.
20. Jia J, Che L, **Cigliano A**, Wang X, Peitta G, Tao J, Zhong S, Ribback S, Evert M, Chen X, Calvisi DF. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis. *Int J Mol Sci*. 2020 Nov 11;21(22):8467. doi: 10.3390/ijms21228467.
21. Shang R, Song X, Wang P, Zhou Y, Lu X, Wang J, Xu M, Chen X, Utpatel K, Che L, Liang B, **Cigliano A**, Evert M, Calvisi DF, Chen X. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. *Gut*. 2021 Sep;70(9):1746-1757. doi: 10.1136/gutjnl-2020-320716.
22. Metzendorf C, Wineberger K, Rausch J, **Cigliano A**, Peters K, Sun B, Mennerich D, Kietzmann T, Calvisi DF, Dombrowski F, Ribback S. Transcriptomic and Proteomic Analysis of Clear Cell Foci (CCF) in the Human Non-Cirrhotic Liver Identifies Several Differentially Expressed Genes and Proteins with Functions in Cancer Cell Biology and Glycogen Metabolism. *Molecules*. 2020 Sep 10;25(18):4141. doi: 10.3390/molecules25184141.
23. Scavo MP, **Cigliano A**, Depalo N, Fanizza E, Bianco MG, Denora N, Laquintana V, Curri ML, Lorusso D, Lotesoriere C, Panarese A, Giannelli G. Erratum to "Frizzled-10 Extracellular Vesicles Plasma Concentration Is Associated with Tumoral Progression in Patients with Colorectal and Gastric Cancer". *J Oncol*. 2020 Jan 30;2020:6153432. doi: 10.1155/2020/6153432. Erratum for: *J Oncol*. 2019 Jun 2;2019:2715968.
24. Zhang S, Zhang J, Evert K, Li X, Liu P, Kiss A, Schaff Z, Ament C, Zhang Y, Serra M, Evert M, Chen N, Xu F, Chen X, Tao J, Calvisi DF, **Cigliano A**. The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic  $\beta$ -Catenin to Induce Hepatoblastoma Development in Mice and Humans. *Am J Pathol*. 2020 Jul;190(7):1397-1413. doi: 10.1016/j.ajpath.2020.03.011.
25. Mancarella S, Serino G, Dituri F, **Cigliano A**, Ribback S, Wang J, Chen X, Calvisi DF, Giannelli G. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. *Cell Death Differ*. 2020 Aug;27(8):2330-2343. doi: 10.1038/s41418-020-0505-4.
26. Che L, Paliogiannis P, **Cigliano A**, Pilo MG, Chen X, Calvisi DF. Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma. *Front Oncol*. 2019 Dec 11;9:1412. doi: 10.3389/fonc.2019.01412.
27. **Cigliano A**, Pilo MG, Mela M, Ribback S, Dombrowski F, Pes GM, Cossu A, Evert M, Calvisi DF, Utpatel K. Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma. *Medicina (Kaunas)*. 2019 Dec 18;56(1):1. doi: 10.3390/medicina56010001.

28. Sannai M, Doneddu V, Giri V, Seeholzer S, Nicolas E, Yip SC, Bassi MR, Mancuso P, Cortellino S, **Cigliano A**, Lurie R, Ding H, Chernoff J, Sobol RW, Yen TJ, Bagella L, Bellacosa A. Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1. *DNA Repair* (Amst). 2019 Oct;82:102687. doi: 10.1016/j.dnarep.2019.102687.
29. Xu M, Wang J, Xu Z, Li R, Wang P, Shang R, **Cigliano A**, Ribback S, Solinas A, Pes GM, Evert K, Wang H, Song X, Zhang S, Che L, Pascale RM, Calvisi DF, Liu Q, Chen X. SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model. *Cancer Res*. 2019 Nov 1;79(21):5563-5574. doi: 10.1158/0008-5472.CAN-18-3750.
30. Scavo MP, **Cigliano A**, Depalo N, Fanizza E, Bianco MG, Denora N, Laquintana V, Curri ML, Lorusso D, Lotesoriere C, Panarese A, Giannelli G. Frizzled-10 Extracellular Vesicles Plasma Concentration Is Associated with Tumoral Progression in Patients with Colorectal and Gastric Cancer. *J Oncol*. 2019 Jun 2;2019:2715968. doi: 10.1155/2019/2715968.
31. Wang J, Wang H, Peters M, Ding N, Ribback S, Utpatel K, **Cigliano A**, Dombrowski F, Xu M, Chen X, Song X, Che L, Evert M, Cossu A, Gordan J, Zeng Y, Chen X, Calvisi DF. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. *J Hepatol*. 2019 Oct;71(4):742-752. doi: 10.1016/j.jhep.2019.05.027.
32. Simile MM, Peitta G, Tomasi ML, Brozzetti S, Feo CF, Porcu A, **Cigliano A**, Calvisi DF, Feo F, Pascale RM. MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes. *Oncotarget*. 2019 Apr 19;10(29):2835-2854. doi: 10.18632/oncotarget.26838.
33. Xu Z, Xu M, Liu P, Zhang S, Shang R, Qiao Y, Che L, Ribback S, **Cigliano A**, Evert K, Pascale RM, Dombrowski F, Evert M, Chen X, Calvisi DF, Chen X. The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans. *Hepatology*. 2019 Nov;70(5):1600-1613. doi: 10.1002/hep.30697.
34. Cao H, Xu Z, Wang J, **Cigliano A**, Pilo MG, Ribback S, Zhang S, Qiao Y, Che L, Pascale RM, Calvisi DF, Chen X. Functional role of SGK3 in PI3K/Pten driven liver tumor development. *BMC Cancer*. 2019 Apr 11;19(1):343. doi: 10.1186/s12885-019-5551-2.
35. Che L, Chi W, Qiao Y, Zhang J, Song X, Liu Y, Li L, Jia J, Pilo MG, Wang J, **Cigliano A**, Ma Z, Kuang W, Tang Z, Zhang Z, Shui G, Ribback S, Dombrowski F, Evert M, Pascale RM, Cossu C, Pes GM, Osborne TF, Calvisi DF, Chen X, Chen L. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. *Gut*. 2020 Jan;69(1):177-186. doi: 10.1136/gutjnl-2018-317581.
36. Zhang J, Liu P, Tao J, Wang P, Zhang Y, Song X, Che L, Sumazin P, Ribback S, Kiss A, Schaff Z, **Cigliano A**, Dombrowski F, Cossu C, Pascale RM, Calvisi DF, Monga SP, Chen X. TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma. *Am J Pathol*. 2019 May;189(5):1077-1090. doi: 10.1016/j.ajpath.2019.01.016.
37. Wang P, Song X, Utpatel K, Shang R, Yang YM, Xu M, Zhang J, Che L, Gordan J, **Cigliano A**, Seki E, Evert M, Calvisi DF, Hu X, Chen X. MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment. *Cell Death Dis*. 2019 Feb 11;10(2):120. doi: 10.1038/s41419-019-1389-4.
38. Dituri F, Mancarella S, **Cigliano A**, Chieti A, Giannelli G. TGF- $\beta$  as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives. *Semin Liver Dis*. 2019 Feb;39(1):53-69. doi: 10.1055/s-0038-1676121.
39. Qiao Y, Xu M, Tao J, Che L, **Cigliano A**, Monga SP, Calvisi DF, Chen X. Oncogenic potential of N-terminal deletion and S45Y mutant  $\beta$ -catenin in promoting hepatocellular carcinoma development in mice. *BMC Cancer*. 2018 Nov 12;18(1):1093. doi: 10.1186/s12885-018-4870-z.
40. Liu X, Song X, Zhang J, Xu Z, Che L, Qiao Y, Ortiz Pedraza Y, **Cigliano A**, Pascale RM, Calvisi DF, Liu Y, Chen X. Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma. *Cancer Med*. 2018 Dec;7(12):6170-6181. doi: 10.1002/cam4.1777.
41. Song X, Liu X, Wang H, Wang J, Qiao Y, **Cigliano A**, Utpatel K, Ribback S, Pilo MG, Serra M, Gordan JD, Che L, Zhang S, Cossu A, Porcu A, Pascale RM, Dombrowski F, Hu H, Calvisi DF, Evert M, Chen X. Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic

- Cholangiocarcinoma. *Clin Cancer Res.* 2019 Jan 1;25(1):403-413. doi: 10.1158/1078-0432.CCR-18-0284.
42. Ribback S, Che L, Pilo MG, **Cigliano A**, Latte G, Pes GM, Porcu A, Pascale RM, Li L, Qiao Y, Dombrowski F, Chen X, Calvisi DF. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma. *Cell Cycle.* 2018;17(12):1496-1512. doi: 10.1080/15384101.2018.1489182.
  43. Zhang S, Wang J, Wang H, Fan L, Fan B, Zeng B, Tao J, Li X, Che L, **Cigliano A**, Ribback S, Dombrowski F, Chen B, Cong W, Wei L, Calvisi DF, Chen X. Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans. *Am J Pathol.* 2018 Apr;188(4):995-1006. doi: 10.1016/j.ajpath.2017.12.017.
  44. Dong M, Liu X, Evert K, Utpatel K, Peters M, Zhang S, Xu Z, Che L, **Cigliano A**, Ribback S, Dombrowski F, Cossu A, Gordan J, Calvisi DF, Evert M, Liu Y, Chen X. Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. *Cell Death Dis.* 2018 Jan 18;9(2):31. doi: 10.1038/s41419-017-0183-4.
  45. Xu Z, Hu J, Cao H, Pilo MG, **Cigliano A**, Shao Z, Xu M, Ribback S, Dombrowski F, Calvisi DF, Chen X. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. *Exp Mol Med.* 2018 Jan 5;50(1):e417. doi: 10.1038/emmm.2017.158.
  46. Ribback S, Sonke J, Lohr A, Frohme J, Peters K, Holm J, Peters M, **Cigliano A**, Calvisi DF, Dombrowski F. Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice. *Oncotarget.* 2017 Nov 1;8(61):104315-104329. doi: 10.18632/oncotarget.22234.
  47. **Cigliano A**, Pilo MG, Li L, Latte G, Szydłowska M, Simile MM, Paliogiannis P, Che L, Pes GM, Palmieri G, Sini MC, Cossu A, Porcu A, Vidili G, Seddaiu MA, Pascale RM, Ribback S, Dombrowski F, Chen X, Calvisi DF. Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. *Oncotarget.* 2017 Oct 3;8(53):90638-90650. doi: 10.18632/oncotarget.21469.
  48. Liu P, Calvisi DF, Kiss A, **Cigliano A**, Schaff Z, Che L, Ribback S, Dombrowski F, Zhao D, Chen X. Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development. *Oncotarget.* 2017 Sep 1;8(43):73433-73447. doi: 10.18632/oncotarget.20622.
  49. **Cigliano A**, Wang C, Pilo MG, Szydłowska M, Brozzetti S, Latte G, Pes GM, Pascale RM, Seddaiu MA, Vidili G, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice. *Oncotarget.* 2017 Apr 7;8(33):54149-54159. doi: 10.18632/oncotarget.16927.
  50. Jia J, Qiao Y, Pilo MG, **Cigliano A**, Liu X, Shao Z, Calvisi DF, Chen X. Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade. *PLoS One.* 2017 Sep 6;12(9):e0184068. doi: 10.1371/journal.pone.0184068.
  51. Zhang S, Song X, Cao D, Xu Z, Fan B, Che L, Hu J, Chen B, Dong M, Pilo MG, **Cigliano A**, Evert K, Ribback S, Dombrowski F, Pascale RM, Cossu A, Vidili G, Porcu A, Simile MM, Pes GM, Giannelli G, Gordan J, Wei L, Evert M, Cong W, Calvisi DF, Chen X. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. *J Hepatol.* 2017 Dec;67(6):1194-1203. doi: 10.1016/j.jhep.2017.07.006.
  52. Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo MG, **Cigliano A**, Pes GM, Pascale RM, Brozzetti S, Vidili G, Porcu A, Cossu A, Palmieri G, Sini MC, Ribback S, Dombrowski F, Tao J, Calvisi DF, Chen L, Chen X. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. *Hepatology.* 2017 Jul;66(1):167-181. doi: 10.1002/hep.29183.
  53. **Cigliano A**, Wang J, Chen X, Calvisi DF. Role of the Notch signaling in cholangiocarcinoma. *Expert Opin Ther Targets.* 2017 May;21(5):471-483. doi: 10.1080/14728222.2017.1310842.
  54. Che L, Pilo MG, **Cigliano A**, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. *Cell Cycle.* 2017 Mar 19;16(6):499-507. doi: 10.1080/15384101.2017.1282586.
  55. Che L, Fan B, Pilo MG, Xu Z, Liu Y, **Cigliano A**, Cossu A, Palmieri G, Pascale RM, Porcu A, Vidili G, Serra M, Dombrowski F, Ribback S, Calvisi DF, Chen X. Jagged 1 is a major Notch ligand along

- cholangiocarcinoma development in mice and humans. *Oncogenesis*. 2016 Dec 5;5(12):e274. doi: 10.1038/oncis.2016.73.
56. Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, **Cigliano A**, Peters K, Pilo MG, Evert M, Calvisi DF, Dombrowski F. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. *Int J Mol Sci*. 2016 Sep 23;17(10):1618. doi: 10.3390/ijms17101618.
  57. Cao D, Song X, Che L, Li X, Pilo MG, Vidili G, Porcu A, Solinas A, **Cigliano A**, Pes GM, Ribback S, Dombrowski F, Chen X, Li L, Calvisi DF. Both de novo synthesized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. *Liver Int*. 2017 Jan;37(1):80-89. doi: 10.1111/liv.13183.
  58. Mahlke C, Hernando D, Jahn C, **Cigliano A**, Ittermann T, Mössler A, Kromrey ML, Domaska G, Reeder SB, Kühn JP. Quantification of liver proton-density fat fraction in 7.1T preclinical MR systems: Impact of the fitting technique. *J Magn Reson Imaging*. 2016 Dec;44(6):1425-1431. doi: 10.1002/jmri.25319.
  59. Li L, Che L, Tharp KM, Park HM, Pilo MG, Cao D, **Cigliano A**, Latte G, Xu Z, Ribback S, Dombrowski F, Evert M, Gores GJ, Stahl A, Calvisi DF, Chen X. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. *Hepatology*. 2016 Jun;63(6):1900-13. doi: 10.1002/hep.28508.
  60. Samarín J, Laketa V, Malz M, Roessler S, Stein I, Horwitz E, Singer S, Dimou E, **Cigliano A**, Bissinger M, Falk CS, Chen X, Dooley S, Pikarsky E, Calvisi DF, Schultz C, Schirmacher P, Breuhahn K. PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells. *Hepatology*. 2016 Mar;63(3):813-26. doi: 10.1002/hep.28357.
  61. Hu J, Che L, Li L, Pilo MG, **Cigliano A**, Ribback S, Li X, Latte G, Mela M, Evert M, Dombrowski F, Zheng G, Chen X, Calvisi DF. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. *Sci Rep*. 2016 Feb 9;6:20484. doi: 10.1038/srep20484.
  62. Ribback S, Calvisi DF, **Cigliano A**, Rausch J, Heidecke CD, Birth M, Dombrowski F. Molekulare und metabolische Veränderungen in humanen klarzelligen Leberherden [Molecular and metabolic changes in human clear cell liver foci]. *Pathologe*. 2015 Nov;36 Suppl 2:210-5. German. doi: 10.1007/s00292-015-0089-9.
  63. Li L, Pilo GM, Li X, **Cigliano A**, Latte G, Che L, Joseph C, Mela M, Wang C, Jiang L, Ribback S, Simile MM, Pascale RM, Dombrowski F, Evert M, Semenkovich CF, Chen X, Calvisi DF. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. *J Hepatol*. 2016 Feb;64(2):333-341. doi: 10.1016/j.jhep.2015.10.004.
  64. Ribback S, **Cigliano A**, Kroeger N, Pilo MG, Terracciano L, Burchardt M, Bannasch P, Calvisi DF, Dombrowski F. PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. *Oncotarget*. 2015 May 30;6(15):13036-48. doi: 10.18632/oncotarget.3675.
  65. Li X, Tao J, **Cigliano A**, Sini M, Calderaro J, Azoulay D, Wang C, Liu Y, Jiang L, Evert K, Demartis MI, Ribback S, Utpatel K, Dombrowski F, Evert M, Calvisi DF, Chen X. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. *Oncotarget*. 2015 Apr 30;6(12):10102-15. doi: 10.18632/oncotarget.3546.
  66. Delogu S, Wang C, **Cigliano A**, Utpatel K, Sini M, Longerich T, Waldburger N, Breuhahn K, Jiang L, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. *Oncotarget*. 2015 Feb 10;6(4):2222-34. doi: 10.18632/oncotarget.2945.
  67. Wang C, **Cigliano A**, Jiang L, Li X, Fan B, Pilo MG, Liu Y, Gui B, Sini M, Smith JW, Dombrowski F, Calvisi DF, Evert M, Chen X. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice. *Hepatology*. 2015 Jan;61(1):200-13. doi: 10.1002/hep.27396.
  68. Tao J, Calvisi DF, Ranganathan S, **Cigliano A**, Zhou L, Singh S, Jiang L, Fan B, Terracciano L, Armeanu-Ebinger S, Ribback S, Dombrowski F, Evert M, Chen X, Monga SPS. Activation of  $\beta$ -catenin and Yap1

- in human hepatoblastoma and induction of hepatocarcinogenesis in mice. *Gastroenterology*. 2014 Sep;147(3):690-701. doi: 10.1053/j.gastro.2014.05.004.
69. Wang C, **Cigliano A**, Delogu S, Armbruster J, Dombrowski F, Evert M, Chen X, Calvisi DF. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. *Cell Cycle*. 2013 Jul 1;12(13):1999-2010. doi: 10.4161/cc.25099.
  70. Ribback S, Calvisi DF, **Cigliano A**, Sailer V, Peters M, Rausch J, Heidecke CD, Birth M, Dombrowski F. Molecular and metabolic changes in human liver clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis. *J Hepatol*. 2013 Jun;58(6):1147-56. doi: 10.1016/j.jhep.2013.01.013.
  71. Wang C, Delogu S, Ho C, Lee SA, Gui B, Jiang L, Ladu S, **Cigliano A**, Dombrowski F, Evert M, Calvisi DF, Chen X. Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. *J Hepatol*. 2012 Sep;57(3):577-83. doi: 10.1016/j.jhep.2012.04.026.
  72. **Cigliano A**, Gandaglia A, Lapedda AJ, Zinellu E, Naso F, Gastaldello A, Aguiari P, De Muro P, Gerosa G, Spina M, Formato M. Fine structure of glycosaminoglycans from fresh and decellularized porcine cardiac valves and pericardium. *Biochem Res Int*. 2012;2012:979351. doi: 10.1155/2012/979351.
  73. Zinellu E, Lapedda AJ, **Cigliano A**, Pisanu S, Zinellu A, Carru C, Bacciu PP, Piredda F, Guarino A, Spirito R, Formato M. Association between Human Plasma Chondroitin Sulfate Isomers and Carotid Atherosclerotic Plaques. *Biochem Res Int*. 2012;2012:281284. doi: 10.1155/2012/281284.
  74. Cortellino S, Xu J, Sannai M, Moore R, Caretti E, **Cigliano A**, Le Coz M, Devarajan K, Wessels A, Soprano D, Abramowitz LK, Bartolomei MS, Rambow F, Bassi MR, Bruno T, Fanciulli M, Renner C, Klein-Szanto AJ, Matsumoto Y, Kobi D, Davidson I, Alberti C, Larue L, Bellacosa A. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. *Cell*. 2011 Jul 8;146(1):67-79. doi: 10.1016/j.cell.2011.06.020.
  75. Naso F, Gandaglia A, Formato M, **Cigliano A**, Lapedda AJ, Gerosa G, Spina M. Differential distribution of structural components and hydration in aortic and pulmonary heart valve conduits: Impact of detergent-based cell removal. *Acta Biomater*. 2010 Dec;6(12):4675-88. doi: 10.1016/j.actbio.2010.06.037.
  76. Capobianco G, de Muro P, Cherchi GM, Formato M, Lapedda AJ, **Cigliano A**, Zinellu E, Dessole F, Gordini L, Dessole S. Plasma levels of C-reactive protein, leptin and glycosaminoglycans during spontaneous menstrual cycle: differences between ovulatory and anovulatory cycles. *Arch Gynecol Obstet*. 2010 Aug;282(2):207-13. doi: 10.1007/s00404-010-1432-2.
  77. Lapedda AJ, **Cigliano A**, Cherchi GM, Spirito R, Maggioni M, Carta F, Turrini F, Edelstein C, Scanu AM, Formato M. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. *Atherosclerosis*. 2009 Mar;203(1):112-8. doi: 10.1016/j.atherosclerosis.2008.07.001.

## CONFERENCE PROCEEDINGS

Participation as speaker and poster presentation in national and international conferences.

1. Frion-Herrera Y, Venturin C, Cadamuro M, Nuozzi G, Radu CM, Mescoli C, Cillo U, Gringeri E, Campello E, Strazzabosco M, **Cigliano A**, Calvisi DF, Simioni P, Fabris L. Activation of coagulation system and platelet aggregation in patients with primary sclerosing cholangitis and cholangiocarcinoma. European Association for the Study of the Liver Congress (EASL), May 2025 Amsterdam, Netherlands (co-author)
2. Frion-Herrera Y, Venturin C, Cadamuro M, Mescoli C, Cillo U, Gringeri E, Campello E, Strazzabosco M, **Cigliano A**, Calvisi DF, Simioni P, Fabris L. Activation of coagulation factors and impaired fibrinolysis in patients with primary sclerosing cholangitis and cholangiocarcinoma. AASLD - The Liver Meeting (TLM), Novembre 2024 San Diego, California (co-author)
3. **Cigliano A**, Gigante I, Serra M, Vidili G, Simile MM, Steinmann S, Urigo F, Cossu E, Ribback S, Pascale RM, Giannelli G, Evert M, Chen X, Calvisi DF. HSF1 is a prognostic factor and therapeutic target in experimental and human cholangiocarcinoma. SIPMet – Translational Pathophysiology,

- September 2024, Udine (author)
4. Coinu S, Ibba R, **Cigliano A**, Carta A, Murineddu G, Piras S. Design and synthesis of novel FGFR inhibitors for the treatment of glioblastoma. AMYC-BIOMED 2024, Rome (co-author)
  5. Coinu S, Ibba R, Riu F, **Cigliano A**, Piras S, Murineddu G, Carta A. Design and synthesis of antileukemia Imatinib-like compounds as BCR-ABL1 protein kinase inhibitors. 31<sup>st</sup> Young Research Fellows Meeting SCT 2024, Grenoble (co-author)
  6. Lupinu I, Ibba R, Piras S, **Cigliano A**, Carta A. Design and synthesis of small molecules as potential Spleen Tyrosine Kinase inhibitors for the treatment of hematological cancers. 31<sup>st</sup> Young Research Fellows Meeting SCT 2024, Grenoble (co-author)
  7. Evert K, **Cigliano A**, Qiao Y, Wang J, Karagoz E, Song X, Xu M, Che L, Tao J, Wang B, Monga SP, Chen X, Evert M, Calvisi DF. Loss of Axin1 induced hepatocarcinogenesis requires intact  $\beta$ -Catenin but not Notch cascade in mice. German Association for the Study of the Liver, GASL 2019, Heidelberg (author)
  8. **Cigliano A**, Utpatel K, Song X, Wang P, Chen X, Evert M, Calvisi DF. MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment. German Association for the Study of the Liver, GASL 2019, Heidelberg (author)
  9. Metzendorf C, Wineberger K, **Cigliano A**, Calvisi DF, Dombrowski F, Ribback S. Proteomic analysis of clear cell foci in the human liver identifies differential expression of Starch-Binding Domain-Containing Protein 1 (STBD1). German Association for the Study of the Liver, GASL 2019, Heidelberg (co-author)
  10. Calvisi DF, Li L, Pilo GM, **Cigliano A**, Ribback S, Dombrowski F, Chen X, Evert M. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice. German Association for the Study of the Liver, GASL 2016, Dusseldorf (author)
  11. Annweiler K, Evert K, **Cigliano A**, Sini M, Latte G, Frau M, Pascale RM, Dombrowski F, Calvisi DF, Evert M, Utpatel K. Different oncogenic potential in the mouse liver of mutant forms of the p110 $\alpha$  catalytic subunit of phosphoinositide-3-kinase (PIK3CA). German Association for the Study of the Liver, GASL 2016, Dusseldorf (author)
  12. Calvisi DF, **Cigliano A**, Wang C, Pilo MG, Sini M, Dombrowski F, Chen X, Evert M. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and NRas protooncogenes in mice. German Association for the Study of the Liver, GASL 2015, (author)
  13. Calvisi DF, Tao J, Ranganathan S, **Cigliano A**, Jiang L, Fan B, Armeanu-Ebinger S, Delogu S, Ribback S, Dombrowski F, Monga SPS, Chen X, Evert M. Synergistische Effekte von Beta-Catenin und YAP führen zur Entstehung von Hepatoblastomen in Mäusen und beim Menschen. German Association for the Study of the Liver, GASL 2014, Tübingen (author)
  14. Calvisi DF, Wang C, Fan B, Jiang L, **Cigliano A**, Delogu S, Dombrowski F, Chen X, Evert M. Complete inhibition of mTORC1 cascade is required to suppress hepatocarcinogenesis induced by AKT and Ras co-expression. German Association for the Study of the Liver, GASL 2013, Hannover (author)
  15. Ribback S, Calvisi DF, **Cigliano A**, Sailer V, Heidecke CD, Birth M, Dombrowski F. Clear cell foci of altered hepatocytes and hepatocellular carcinomas in the N-Nitrosomorpholine (NNM) model in the rat show an overexpression of pro-oncogenic pathways and metabolic alterations similar to lesions in the islet-transplantation model. German Association for the Study of the Liver, GASL 2013, Hannover (co-author)
  16. Pisanu S, Zinellu A, Lepedda AJ, Zinellu E, **Cigliano A**, Cherchi GM, Sotgia S, Carru C, Deiana L, Formato M. New Capillary Zone Electrophoresis (CZE) method for glycosaminoglycan analysis. XXVI Riunione Società Italiana per lo Studio del Connettivo 26-27 Ottobre 2006 Università degli Studi di Padova (co-author)
  17. Zinellu E, Pisanu S, Zinellu A, Lepedda AJ, **Cigliano A**, Spirito R, Guarino A, Sanna GM, Carru C, Deiana L, Formato M. Structural analysis of plasma glycosaminoglycans in patients with atheromatous lesions. XXVI Riunione Società Italiana per lo Studio del Connettivo 26-27 Ottobre 2006 Università degli Studi di Padova (co-author)

## **LANGUAGE**

<b>Italiano</b>	Mothertongue		
<b>Inglese</b>	Speaking: B2	Writing: B2	Listening: B2
<b>Tedesco</b>	Basic knowledge		

## **SCIENTIFIC SOCIETY**

Since 2018 Member of ENS-CCA “European Network for the Study of Cholangiocarcinoma”

Since 2022 Member of SISC “Italian Society for the study of Connective Tissue”

Since 2024 Member of SIPMeT “Italian Society of Pathology and Translational Medicine”

## **AWARDS**

Program ‘Master&Back’ financed by “Regione Sardegna – Italy” to carry out an internship as Visiting Scientist at Fox Chase Cancer Center Philadelphia (US). Call 2007-2008 – Identifier T2-MAB-A2008-467.

I hereby declare that all the information provided in this resume is complete and correct according to articles 46 and 47 of D.P.R. 445/2000 Italian Law.

Sassari, 01/10/2025